## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.45 indicates fundamental undervaluation. Quality metrics strong (ROE 37%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($77.15)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. How Investors Are Reacting To Solventum (SOLV) Expert Guidance Expanding Use Of Prevena ciNPT Dressings**
- Source: Simply Wall Street | 20251221T150806 | Somewhat-Bullish | Relevance: 100%
- Solventum recently announced updated expert recommendations in the International Wound Journal expanding the clinical use of its Prevena dressings for closed incision negative pressure therapy (ciNPT). This development, coupled with Solventum's authorized share repurchases and improved earnings guidance, frames an investment narrative focused on high-value therapies and balance sheet repair. While positive for product adoption, investors still face execution risks associated with the company's multi-year ERP program and ongoing separation from 3M.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.45 suggests fair value with growth premium. Forward P/E 12.7x stretched relative to 6% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.0B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.45 |
| Forward P/E | 12.7 |
| Current P/E | 13.4 |
| YoY Growth | 5.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 7.4pp (needs >4.0% for momentum thesis). Underperforming sector by 3.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.72), momentum weakening. RSI neutral at 51. Elevated volume (1.5x 20MA), institutional activity likely. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.41% (CS: 16) | Weak |
| RSI_14 | 51.0 | Neutral |
| MACD Histogram | -0.72 | Bearish |
| vs SMA20 | 0.972x | Below |
| vs SMA50 | 1.052x | Above |
| vs SMA200 | 1.099x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $80.77
- **Stop Loss:** $77.15 (4.5% risk)
- **Target:** $88.01 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 331
- **Position Value:** $26,734.87
- **Portfolio %:** 26.73%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*